Revolutionising Cancer Care

The Mark Foundation Institute for Integrated Cancer Medicine (MFICM) hosted at the University of Cambridge, with funding from The Mark Foundation for Cancer Research and the Cancer Research UK Cambridge Centre, aims to revolutionise cancer care by re-inventing the treatment pathway for patients.

Re-inventing the Patient Pathway

Research Areas

Breast Cancer

Read more Arrow

Ovarian Cancer

Read more Arrow

Pancreatic Cancer

Read more Arrow

Renal Cancer

Read more Arrow

Latest Updates

You can find a full list of media coverage about MFICM on the News page

Partner trial results give hope for treating inherited breast cancers

Partner trial results give hope for treating inherited breast cancers

Article co-authored by Professor Jean Abraham published in Nature Communications

Read More Arrow
Assessment of cancer biomarkers in the Grenfell firefighter cohort study

Assessment of cancer biomarkers in the Grenfell firefighter cohort study

Article co-authored by CMDL Director, Shubha Anand was published recently.

Read More Arrow
AI-powered analysis of data from NAXIVA helps researchers predict which patients will respond to treatment for kidney cancer

AI-powered analysis of data from NAXIVA helps researchers predict which patients will respond to treatment for kidney cancer

Article “Angiogenic and immune predictors of neoadjuvant axitinib response in renal cell carcinoma with venous tumour thrombus” published in Nature Communications.

Read More Arrow

Key statistics

 
 
 
 
 
 
Statistics map
Connect

Connect with us

The Mark Foundation Institute for Integrated Cancer Medicine (MFICM) at the University of Cambridge aims to revolutionise cancer care by affecting patients along their treatment pathway.

Find out more

Connect